Clinical trial
Nefazodone in the Treatment of Social Phobia
NCT00231348 · Emory University, Other · Completed
Key facts
| NCT number | NCT00231348 |
|---|---|
| Title | Nefazodone in the Treatment of Social Phobia |
| Official title | Nefazodone in the Treatment of Social Phobia: Functional Brain Imaging and Neuroendocrine Correlates |
| Lead sponsor | Emory University, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Social Anxiety Disorder (SAD) |
| Intervention type | Drug |
| Interventions | Nefazodone |
| Enrollment | 24 |
| Completion | Apr 1, 2000 |
| First posted | Oct 4, 2005 |
| Last update posted | Nov 13, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: